Market Size of Global Mycoplasma Testing Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 13.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Mycoplasma Testing Market Analysis
The mycoplasma testing market is estimated to register a healthy CAGR of 13% over the forecast period, 2022-2027.
In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. The study "The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic" published in April 2022, stated that the M. pneumoniae outbreak started in the summer of 2019 in Beijing. After the COVID-19 pandemic outbreak at the end of 2019, the M. pneumoniae positive rates dropped dramatically. This was due to the restrictive measures of the COVID-19 pandemic, which effectively controlled the transmission of M. pneumonia. However, after the easing of COVID-19 restrictions, M. pneumonia is expected to increase further during the study period, thereby impacting the market growth.
Factors such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing.
The study "Point-of-care molecular diagnosis of Mycoplasma pneumonia including macrolide sensitivity using quenching probe polymerase chain reaction" published in October 2021, stated that the Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. Thus, such studies indicating the potential of diagnostic testing for mycoplasma pneumonia will increase their acceptance, thus driving the market.
In April 2022, AlphaBiolabs launched STI testing for members of the public and healthcare partners. The Complete Panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias. Therefore, the launch of such tests detecting mycoplasma bacteria will boost the market. Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.
